Indivior Share Discussion Threads

[la forge] 14/2/2020 08:24

----
3. Details of person subject to the notification obligation (iv)
Name FIL Limited
City and country of registered office Pembroke, Bermuda
(if applicable)
4. Full name of shareholder(s) (if different from 3.) (v) See Section
9
Name
--------------------------------------------
City and country of registered office
(if applicable)
--------------------------------------------
5. Date on which the threshold was 12 February 2020
crossed or reached (vi) :
--------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 13 February 2020
--------------------------------------------
5.01%

[entropick] 14/2/2020 05:57

Indivior shares are ‘attractive’, says Numis
Indivior (#INDV), maker of addiction treatment drugs, may have reported a £42m loss in the fourth quarter but Numis believes the shares are ‘highly attractive’.

[buywell3] 14/2/2020 01:00

buywell3 - 23 Nov 2018 - 01:21:03 - 182 of 349

INDIVIOR THE PILL WITH NO CHEERS OR BEERS - INDV

What a bunch of tw@ts that took this to 500p in 2018

And that was after the chances of USA legal actions were known

Amazing the amount of investors funds that have been squandered

Do some still buying thinking that a small company based outside the USA in the UK is going to win a ruling in their favor in American courts ?

Averaging down is not a wise thing when the facts are very much V the reality of the situation

USA BIG PHARMA is running the show



Buyers of this share are taking on the USA BIG PHARMA lobby in the states ... and the FDA and other regulatory USA bodies

Who is going to win ?

[waldron] 13/2/2020 16:54

Price (GBX) 39.57 Var % (+/-) -19.57% (Down -9.63)
High 47.57 Low 35.62
Volume 17,805,287 Last close 39.57 on 13-Feb-2020
Bid 38.75 Offer 39.47
Trading status Closing Price Crossing Special conditions NONE

[robizm] 13/2/2020 13:06

Gamble on court case red or black. Cash more than covers market cap and the injectable drug is picking up. The 2020 outlook will also get marked up as well.

[waldron] 13/2/2020 12:39

30 to 40p$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$$$

[adrian j boris] 13/2/2020 12:38

Price (GBX) 38.73 Var % (+/-) -21.28% (Down -10.47)
High 47.57 Low 38.49
Volume 8,871,073 Last close 49.20 on 12-Feb-2020
Bid 38.55 Offer 38.73
Trading status Regular Trading Special conditions NONE

[adrian j boris] 13/2/2020 12:30

CITYAM

Thursday 13 February 2020 11:02 am
Indivior swings to $42m loss as opioid treatment prices fall
Edward Thicknesse

Drugmaker Indivior saw its shares slump nearly 20 per cent this morning after the firm booked a loss for the fourth quarter on the back of falling prices for its flagship opioid treatment.
(via Getty Images)

Drugmaker Indivior saw its shares slump nearly 20 per cent this morning after the firm booked a loss for the fourth quarter on the back of falling prices for its flagship opioid treatment.
The figures

Indivior, which is best known for its opioid addiction products, swung to a $42m (£32.4m) loss for the last three months of the year, down from a £20m profit in the same period last year.

Read more: Shares in under-fire drugmaker Indivior tick up after positive forecasts

Revenue for the period fell 44 per cent year-on-year, from $236m to $133m this year.

Profit for the whole year fell 39 per cent to $178m, down from $292m last year. Whole year revenue fell 22 per cent to $785m.

The firm forecast a net loss of $20m to $50m for the coming year, excluding exceptional charges.
Why it’s interesting

Indivior’s shares have also plunged, by nearly two-thirds in 2019, as it also battles a potentially crushing $3bn fine for illegally marketing opioid Suboxone.

Sign up to City A.M.’s Midday Update newsletter, delivered to your inbox every lunchtime

The FTSE 250 firm is facing 28 charges of health care fraud, wire fraud, mail fraud, and conspiracy, in connection with the marketing of the product.

The treatment has also seen its market share fall from 53 per cent to 24 per cent over the course of the year as rivals undercut prices with copycat treatments.

The case is a blow for Indivior, which has gained from the government’s efforts to combat the opioid epidemic and is focusing on newer drugs such as Sublocade, an injectable treatment, to boost sales.
What Indivior said

Shaun Thaxter, the firm’s chief executive, said: “2019 was a challenging year for Indivior but I am proud that it brought out the very best in our people as we focused our efforts on improving the lives of patients suffering from addiction and its co-occurring disorders.

Read more: GSK falls short of forecasts as firm prepares to split

“Although we are optimistic about delivering on our strategic priorities in 2020, we of course recognise the legal uncertainties we face.

“We are proactively working to manage these risks while our teams remain focused on leveraging the strategic and operational accomplishments of the past year to further our leadership position in addiction science and diversification into behavioural health.”

[adrian j boris] 13/2/2020 11:02

ashdeans
13 Feb '20 - 10:22 - 2403 of 2404 (Filtered)


0 0 0

YOU SHOULD GIVE MORE DETAILS AS TO ARTICLE

[adrian j boris] 13/2/2020 09:33

Oliver Haill

09:04 Thu 13 Feb 2020

Follow Oliver on:
viewIndivior PLC
Indivior expects to swing to 2020 loss as Suboxone sales keep falling

Revenues fell 22% last year, primarily due to the erosion of market share for its historical leading product, Suboxone Film for opioid addiction
Indivior PLC -

Indivior PLC (LON:INDV) reported a 39% decline in profits for 2019 and said it is likely to fall into losses this year as its key opioid dependency treatment continues to lose ground to generic competition and it invests in marketing new treatments.

Revenues came in at US$785mln for last year, down 22%, primarily due to the erosion of market share for its historical leading product, Suboxone Film for opioid addiction. This was in line with the guidance given by the company in October.

This was only slightly offset by revenue from its new longer-lasting Sublocade treatment, which is given via injection of a 'depot' under the skin, of US$72mln compared to US$12mln a year earlier, together with a revenue contribution from Indivior’s own generic version of Suboxone.

Adjusted operating profit fell 39% to US$202mln while reported post-tax profit fell 51% to US$134m.

The year ended with just over US$1bn cash in the bank, with net cash at US$821mln.

Chief executive Shaun Thaxter said 2019 was “a challenging year” but said 2020 “is shaping up to be a pivotal year” as the company continues its direct-to-consumer campaign to support Sublocade and launches Perseris, an injected 'depot' to treat schizophrenia.

For 2020, assuming Suboxone’s market share is eroded in line with industry expectations, net revenue is expected to fall by up to a third to US$525-585mln, of which Sublocade is expected to contribute US$150-200mln and Perseris US$15-25mln.

This is seen leading to a net loss of US$50-20mln excluding exceptional items and at constant exchange rates.

Indivior also still carries a provision of US$438m relating to US Department of Justice litigation matters, for which it is trying to reach a settlement.
Quick facts: Indivior PLC

Price: 40.11 GBX
LSE:INDV
Market:
LSE
Market Cap:
£292.69 m
Follow
Sep '19Oct '19Nov '19Dec '19Jan '20Feb '2040506070016MZoom1m3m6m1yFromAug 13, 2019To
Feb 13, 2020Highcharts.com

Add related topics to MyProactive

[tcarter66208] 13/2/2020 08:02

Really? Lol

[kw9143] 13/2/2020 08:00

results looks excellent and bod are on top of things. share price will sky rocket to 60p minimum today.

[steeplejack] 13/2/2020 07:28

2019 FY Net Income of $176 at mid point of expectations made at time of third Qtr figures.Sublocade revenue of $72m exceeds top end of forecasts of $70m.

[sarkasm] 12/2/2020 16:23

Price (GBX) 48.68 Var % (+/-) +6.10% (Up +2.80)

High 48.68 Low 45.76

Volume 2,302,716 Last close 45.88 on 11-Feb-2020

Bid 48.42 Offer 48.68

[youngers] 12/2/2020 16:09

Still my best guess on results. Find out how close I was tomorrow.

Totally agree that any litigation update is far more important though and will drive price either positive or negative